Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)

NCT03547700 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

11

Enrollment

OTHER

Sponsor class

Stopped Lack of accrual

Conditions

Lymphoma, T-Cell, Peripheral

Interventions

DRUG: Romidepsin
DRUG: Ixazomib

Sponsor

University of Michigan Rogel Cancer Center

Collaborators

[object Object]
[object Object]